Cabometyx cabozantinib: Additional Phase III data

Additional data from the open-label, international Phase III METEOR trial in 658 metastatic RCC patients who progressed after >=1 VEGF receptor tyrosine kinase inhibitor (TKI) showed that once-daily 60 mg oral Cabometyx led to a median OS, a secondary endpoint, of 21.4 months vs. 16.5 months for once-daily 10 mg oral Afinitor everolimus (HR=0.66, 95% CI: 0.53, 0.83, p=0.0003). Exelixis has previously reported data from the trial (see BioCentury, July 27, 2015; Oct. 5, 2015; Jan. 11, 2016 & Feb. 8, 2016). ...